BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

787 related articles for article (PubMed ID: 11585760)

  • 41. Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with acute lymphoblastic leukemia.
    Xu B; Li L; Tang JH; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1207-10. PubMed ID: 16234090
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic significance of FLT3 ITD and D835 mutations in AML patients.
    Sheikhha MH; Awan A; Tobal K; Liu Yin JA
    Hematol J; 2003; 4(1):41-6. PubMed ID: 12692519
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia.
    Galimberti S; Rossi A; Palumbo GA; Morabito F; Guerrini F; Vincelli I; Fazzi R; Santini V; Petrini M
    Anticancer Res; 2003; 23(4):3419-26. PubMed ID: 12926083
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia.
    Al-Tonbary Y; Mansour AK; Ghazy H; Elghannam DM; Abd-Elghaffar HA
    Int J Lab Hematol; 2009 Jun; 31(3):320-6. PubMed ID: 18336585
    [TBL] [Abstract][Full Text] [Related]  

  • 45. C/EBPA gene mutation and C/EBPA promoter hypermethylation in acute myeloid leukemia with normal cytogenetics.
    Lu Y; Chen W; Chen W; Stein A; Weiss LM; Huang Q
    Am J Hematol; 2010 Jun; 85(6):426-30. PubMed ID: 20513120
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.
    Callens C; Chevret S; Cayuela JM; Cassinat B; Raffoux E; de Botton S; Thomas X; Guerci A; Fegueux N; Pigneux A; Stoppa AM; Lamy T; Rigal-Huguet F; Vekhoff A; Meyer-Monard S; Ferrand A; Sanz M; Chomienne C; Fenaux P; Dombret H;
    Leukemia; 2005 Jul; 19(7):1153-60. PubMed ID: 15889156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.
    Kottaridis PD; Gale RE; Frew ME; Harrison G; Langabeer SE; Belton AA; Walker H; Wheatley K; Bowen DT; Burnett AK; Goldstone AH; Linch DC
    Blood; 2001 Sep; 98(6):1752-9. PubMed ID: 11535508
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
    Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
    Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FMS-like tyrosine kinase 3 internal tandem duplication and the patterns of its gene sequence in 207 Chinese patients with de novo acute myeloid leukemia.
    Zhong L; Jia YQ; Meng WT; Ni X
    Arch Pathol Lab Med; 2012 Jan; 136(1):84-9. PubMed ID: 22208491
    [TBL] [Abstract][Full Text] [Related]  

  • 50. FLT3 mutations in acute myeloid leukemia cell lines.
    Quentmeier H; Reinhardt J; Zaborski M; Drexler HG
    Leukemia; 2003 Jan; 17(1):120-4. PubMed ID: 12529668
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy.
    Christiansen DH; Pedersen-Bjergaard J
    Leukemia; 2001 Dec; 15(12):1848-51. PubMed ID: 11753604
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Correlation of Fms-like tyrosine kinase 3 (FLT3) gene expression to FLT3/internal tandem duplication mutation in peripheral blood of acute myeloid leukemia.].
    Xu B; Shi PC; Song XY; Tang JH; Zhou SY
    Ai Zheng; 2009 Jun; 28(6):632-6. PubMed ID: 19635202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia].
    Wu DP; Yan LZ; Yang L; Chen SN; Wu XJ; Liang JY
    Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):907-10. PubMed ID: 18261272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.
    Steudel C; Wermke M; Schaich M; Schäkel U; Illmer T; Ehninger G; Thiede C
    Genes Chromosomes Cancer; 2003 Jul; 37(3):237-51. PubMed ID: 12759922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.
    Del Poeta G; Ammatuna E; Lavorgna S; Capelli G; Zaza S; Luciano F; Ottone T; Del Principe MI; Buccisano F; Maurillo L; Panetta P; de Fabritiis P; Stasi R; Venditti A; Amadori S; Lo Coco F
    Br J Haematol; 2010 May; 149(3):383-7. PubMed ID: 20148885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML.
    Li W; Zhang L; Huang L; Mi Y; Wang J
    Leuk Res; 2012 Feb; 36(2):186-91. PubMed ID: 21907407
    [TBL] [Abstract][Full Text] [Related]  

  • 60. AML1B transcriptional repressor function is impaired by the Flt3-internal tandem duplication.
    Takahashi S; Harigae H; Kameoka J; Sasaki T; Kaku M
    Br J Haematol; 2005 Aug; 130(3):428-36. PubMed ID: 16042694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.